Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $227K fell 7.0% year over year, behind the +7.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +307.8% a year.
Context
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.0% toward the trailing-twelve-month pace of +7.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.02M USD
- Year-over-year change
- +21.2%
- 3-year CAGR
- +307.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.02M | +21.2% |
| FY2024 | 2024-12-31 | 839K | +649.1% |
| FY2023 | 2023-12-31 | 112K | +646.7% |
| FY2022 | 2022-12-31 | 15K | — |
Cost of Revenue vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 cost of revenue of $1M is the 5th highest of the 10 companies compared; the peer median is $574K.
- Its year-over-year change of +7.4% is the 4th highest of 6, against a peer median of +24.5%.
- Cost of revenue amounts to 5.0% of revenue for RAPP, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $79.33M | -6.2% | +106.1% | 6.6% | |
| LTM Sep 2026 | $77.55M | -68.5% | -90.3% | — | |
| LTM Jun 2026 | $52.53M | +24.5% | +109.0% | 6.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.01M | — | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +307.8% | 5.0% |
| LTM Mar 2026 | $574K | +69.3% | +0.2% | — | |
| LTM Mar 2026 | $284K | +67.1% | +24.6% | — | |
| LTM Mar 2026 | $129K | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $82K | — | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $79K | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $574K | +24.5% | +24.6% | 6.7% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 112K | 839K | 1.02M |
| Gross Profit | (15K) | (112K) | (839K) | (1.02M) |
| Gross Margin | — | — | — | — |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| Depreciation & Amortization | 15K | 112K | 839K | 1.02M |
| EBITDA | (10.35M) | (34.66M) | (77.47M) | (124.08M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (10.37M) | (36.18M) | (83.06M) | (125.1M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income / Expenses | (285K) | 1.4M | 4.75M | 13.62M |
| Income Before Tax | (10.65M) | (34.78M) | (78.31M) | (111.48M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 10K | 0 | 0 |
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.29) | (0.95) | (3.78) | (2.86) |
| EPS (Diluted) | (0.29) | (0.95) | (3.78) | (2.86) |
| Weighted Avg Shares | 20.12M | 18.08M | 20.74M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.12M | 18.08M | 20.74M | 46.98M |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.